Otto, F., Thornell, A.P., Crompton, T., Denzel, A., Gilmour, K.C., Rosewell, I.R., Stamp, G.W.H., Beddington, R.S.P., Mundlos, S., Olsen, B.R., Selby, P.B. and Owen, M.J. (1997). Cbfa1, a Candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell, 89, 765-771. http://dx.doi.org/10.1016/S0092-8674(00)80259-7

has been cited by the following article:

• TITLE: Prohibitins, novel vitamin K2 target factors in osteoblast

  AUTHORS: Tatsuya Uebi, Makoto Umeda, Naoya Maekawa, Satoshi Karasawa, Hiroshi Handa, Takeshi Imai

  KEYWORDS: Vitamin K2; Prohibitin; Osteoblast; Runt-Related Transcription Factor 2 (Runx2)

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.1 No.3, December 12, 2013

  ABSTRACT: Vitamin K2 (VK2, menaquinone) is a drug for osteoporosis. VK2 acts as a cofactor for γ-glutamyl carboxylase, which catalyzes the carboxylation of specific glutamic acid residues (γ-carboxylation) of substrate proteins. Here we demonstrate that VK2 also regulate osteoblastgenic marker gene expression. Using VK2-immobilzed nanobeads new target proteins were purified and identified from osteoblastic cell line. They are prohibitin 1 and 2 (PHB1 & 2), respectively. To confirm the PHBs function on VK2-dependent transcription, PHB1 & 2 were knock-down and osteocalcin gene 2 transcriptions were analyzed, indicating that PHBs regulate VK2-dependent transcription. Taken together PHBs are VK2 target proteins for osteoblastgenic transcription.